| Type of Facility | Number (%) |
|---|---|
| University hospitals | 928 (38.6) |
| Public hospitals (500 beds or more) | 355 (14.8) |
| Public hospitals (499 beds or less) | 401 (16.7) |
| Private hospitals (500 beds or more) | 186 (7.7) |
| Private hospitals (499 beds or less) | 365 (15.2) |
| Hospitals specialized in cancer treatment | 115 (4.8) |
| Clinics | 3 (0.1) |
| Corporations | 7 (0.3) |
| Others | 42 (1.7) |
| Designated Core Hospital for Cancer Genomic Medicine | 192 (8.0) |
| Designated Hospital for Cancer Genomic Medicine | 358(14.9) |
| Cooperative Cancer Genome Hospital | 746(31.1) |
| None of the above | 887(36.9) |
| Unsure if their institution fell into any of the above categories | 219 (9.1) |
| Specialties | Number |
|---|---|
| Gastroenterological Surgery | 548 (22.8) |
| Gastroenterology | 229 (9.5) |
| Urology | 181 (7.5) |
| Obstetrics and Gynecology | 181 (7.5) |
| Respiratory Medicine | 178 (7.4) |
| Dentistry and Oral Surgery | 136 (5.7) |
| Breast Surgery | 133 (5.5) |
| Respiratory Surgery | 116 (4.8) |
| Otorhinolaryngology | 96 (4.0) |
| Hematology | 85 (3.5) |
| Radiation Therapy | 81 (3.4) |
| Pediatrics | 60 (2.5) |
| Oncology | 56 (2.3) |
| Department of Neurosurgery | 56 (2.3) |
| Plastic surgery | 53 (2.2) |
| Gynecology | 44 (1.8) |
| Dermatology | 26 (1.1) |
| Pediatric Surgery | 22 (0.9) |
| Radiology | 17 (0.7) |
| Other Surgery | 10 (0.4) |
| Radiation Diagnosis | 9 (0.4) |
| Other Internal Medicine | 6 (0.2) |
| Oncologic Surgery | 6 (0.2) |
| Pathology | 6 (0.2) |
| Circulatory Medicine | 4 (0.2) |
| Nephrology | 1 (0.0) |
| Transplantation Surgery | 1 (0.0) |
| Ophthalmology | 1 (0.0) |
| Other | 60 (2.5) |
| Cancer Genome Hospitals n (%) |
Noncancer Genome Hospitals n (%) |
p | OR | 95%CI | |
|---|---|---|---|---|---|
| I know that the insurance coverage was added in June 2019 | 975 (75.2) | 502 (45.4) | <0.0001 | 3.7 | 3.1-4.4 |
| I know that the health insurance coverage is limited to patients with a favorable Performance Status (PS) following completion of standard treatment and patients with rare cancers | 972 (75.0) | 514 (46.5) | <0.0001 | 3.5 | 2.9-4.1 |
| I know that the quality of the pathology specimen is a factor in the outcome of the analysis | 1151 (88.8) | 731 (66.1) | <0.0001 | 4.1 | 3.3-5.1 |
| I know that the chances of a cancer genome panel test leading to treatment are about 10% | 1041 (80.3) | 564 (51.0) | <0.0001 | 3.9 | 3.3-4.7 |
| I know that, with individual consent, genetic mutation information and clinical data will be centralized in C-CAT established within the National Cancer Center. | 776 (59.9) | 307 (27.8) | <0.0001 | 3.9 | 3.3-4.6 |
| I know that this test may lead to a diagnosis of a hereditary tumor. | 1135 (87.6) | 762 (68.9) | <0.0001 | 3.2 | 2.6-3.9 |
| Responders From Cancer Genome Hospitals n = 729 (%) |
Responders From Noncancer Genome Hospitals n = 341 (%) |
p | OR | 95%CI | |
|---|---|---|---|---|---|
| Whether the patient is eligible for the test or not | 530 (72.7) | 245 (71.8) | >0.05 | 1.0 | 0.8-1.4 |
| Test details | 459 (63.0) | 197 (57.8) | >0.05 | 1.2 | 0.9-1.6 |
| Expected benefits of the test | 412 (56.5) | 174 (51.0) | >0.05 | 1.2 | 1.0-1.6 |
| Whether the test can be performed at their facility | 310 (42.5) | 121 (35.5) | <0.05 | 1.3 | 1.0-1.8 |
| Cost | 248 (34.0) | 84 (24.6) | <0.05 | 1.6 | 1.2-2.1 |
| Other | 9 (1.2) | 2 (0.6) | >0.05 | 2.1 | 0.4-20.2 |
